Inactive Instrument

Other languages Catabasis Pharmaceuticals Inc Nasdaq

Equities

US14875P1075

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee	Apr. 09
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	Mar. 25
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04
Astria Therapeutics Shares Rise After Pricing of $125 Million Underwritten Offering	Jan. 30
Astria Therapeutics Files $500 Million Mixed Shelf	Dec. 15
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Astria Therapeutics, Inc. Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	Nov. 10
Indian Equities End Lower on Profit Booking; IT Tops Laggards	23-10-12
Astria Therapeutics Prices Common Stock, Warrants Offering for Expected Gross Proceeds of About $64 Million	23-10-12
Glenmark Pharma Unit Licenses Antibody Portfolio to Astria Therapeutics	23-10-12
Ichnos Sciences Enters Licensing Agreement for Ox40 Antibody Portfolio with Astria Therapeutics	23-10-11
Astria Therapeutics Secures Exclusive Global License with Ichnos Sciences for OX40 Portfolio in Atopic Dermatitis Treatment	23-10-11
Astria Therapeutics, Inc. Announces Exclusive Worldwide License Agreement with Ichnos Sciences for Ox40 Portfolio	23-10-11
Astria Therapeutics, Inc. Announces Publication of Star-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics	23-08-31
Astria Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
Astria Therapeutics' Genetic Disorder Drug Candidate Granted FDA Fast-Track Designation	23-07-20
Astria Therapeutics, Inc. Receives Fast Track Designation for Star-0215 for the Treatment of Hereditary Angioedema	23-07-20
Astria Therapeutics, Inc. Appoints John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations	23-07-17
Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Astria Therapeutics, Inc. Promotes Andrea Matthews to Chief Business Officer	23-04-19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Catabasis Pharmaceuticals Inc Nasdaq

Equities

US14875P1075

Other languages

Filters